Roivant flips ulcerative colitis drug to Roche for $7.1B, less than a year after getting the drug from Pfizer

Max Gelman

Senior Editor

Kyle LaHucik

Senior Reporter

Roivant will sell its potential blockbuster ulcerative colitis drug to Roche for $7.1 billion, less than a year after acquiring it from Pfizer for what …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Roivant flips ulcerative colitis drug to Roche for $7.1B, less than a year after getting the drug from Pfizer

Max Gelman

Senior Editor

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

Amgen names Stanford geneticist and biotech founder to CSO post

Kyowa Kirin acquires ex-US rights to Kura’s leukemia treatment for $330M upfront

FDA updates label of 33-year-old cancer drug with new dose and warning

NewAmsterdam aces Phase 3 trial, but investors are skeptical

Are programs with compounded GLP-1s safe for your population?

Roivant flips ul­cer­a­tive col­i­tis drug to Roche for $7.1B, less than a year af­ter get­ting the drug from Pfiz­er

Senior Editor

Senior Reporter

Sign up to read this article for free.

Roivant flips ulcerative colitis drug to Roche for $7.1B, less than a year after getting the drug from Pfizer